Ignite Creation Date:
2024-05-06 @ 7:47 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06136949
Status:
RECRUITING
Last Update Posted:
2023-11-18
First Post:
2023-10-30
Brief Title:
The Theranostic Value of STARD3 in Colorectal Cancer The STAR Study
Sponsor:
Centro di Riferimento Oncologico - Aviano
Organization:
Centro di Riferimento Oncologico - Aviano
Study Overview
Official Title:
The Theranostic Value of STARD3 in Colorectal Cancer The STAR Study a Monocentric Observational Study
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STAR
Brief Summary:
This study aims at verifying the overexpression of STARD3 in both early and advanced CRC patients derived tissues to identify the pathways underpinning tumorigenesis and cancer progression in which STARD3 is involved Moreover its role as a dynamic biomarker of treatment response and its part in treatment sensitivity will be explored
Detailed Description:
Colorectal cancer CRC is one of the most prevalent and deadly tumours in both men and women worldwide An RNAi screening on 214 potential oncogenes described by the TCGA was performed and STARD3 was identified as potential theranostic target in mCRC Considering the effects on cell viability and the druggability STARD3 represents a strong candidate as a valid diagnostic and therapeutic target for mCRC patients
In recent years organoids have become a research hotspot showing a significant potential in the biological analysis of tumours Patient derived organoids could be a viable platform to test clinically available drugs andor promising new molecules to explore tumour sensitivity in an ex-vivo model
This is a longitudinal observational study on CRC patients derived tissues to verify the overexpression of STARD3 in both early and advanced CRC patients to identify the pathways underpinning tumorigenesis and cancer progression in which STARD3 is involved through the development of cancer derived organoids to explore its role as a dynamic biomarker of treatment response and to demonstrate its part in treatment sensitivity measured in tumour derived organoids compared to drug sensitivity observed in real-world patients
In recent years organoids have become a research hotspot showing a significant potential in the biological analysis of tumours Patient derived organoids could be a viable platform to test clinically available drugs andor promising new molecules to explore tumour sensitivity in an ex-vivo model
This is a longitudinal observational study on CRC patients derived tissues to verify the overexpression of STARD3 in both early and advanced CRC patients to identify the pathways underpinning tumorigenesis and cancer progression in which STARD3 is involved through the development of cancer derived organoids to explore its role as a dynamic biomarker of treatment response and to demonstrate its part in treatment sensitivity measured in tumour derived organoids compared to drug sensitivity observed in real-world patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None